Original Research
Published on 13 Jan 2023
Neutralization of excessive CCL28 improves wound healing in diabetic mice
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1087924
- 2,969 views
- 2 citations
Type at least 3 characters
1,623 articles
Articles
Original Research
Published on 13 Jan 2023
Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1090261
- 2,914 views
- 8 citations
Review
Published on 13 Jan 2023
Ferroptosis as a therapeutic target for inflammation-related intestinal diseases
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1095366
- 6,670 views
- 23 citations
Editorial
Published on 12 Jan 2023
Editorial: Anti-inflammatory immunopharmacology in the prevention and treatment of major chronic diseases
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1134918
- 1,047 views
- 1 citation
Editorial
Published on 11 Jan 2023
Editorial: Natural compounds regulating epigenetics for treating chronic inflammatory diseases
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1121165
- 1,070 views
Original Research
Published on 10 Jan 2023
Truncated-semaphorin3A is a potential regulatory molecule to restore immune homeostasis in immune-mediated diseases
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1085892
- 2,166 views
- 3 citations
Original Research
Published on 10 Jan 2023
Arbitrary Ca2+ regulation for endothelial nitric oxide, NFAT and NF-ÎşB activities by an optogenetic approach
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1076116
- 1,751 views
Brief Research Report
Published on 10 Jan 2023
Brief research report: Repurposing pentoxifylline to treat intense acute swimming–Induced delayed-onset muscle soreness in mice: Targeting peripheral and spinal cord nociceptive mechanisms
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.950314
- 1,426 views
Original Research
Published on 09 Jan 2023
Role of M1 macrophages in diabetic foot ulcers and related immune regulatory mechanisms
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1098041
- 3,957 views
- 2 citations
Original Research
Published on 06 Jan 2023
Identification of ferroptosis, necroptosis, and pyroptosis-associated genes in periodontitis-affected human periodontal tissue using integrated bioinformatic analysis
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1098851
- 9,849 views
- 14 citations
Correction
Published on 05 Jan 2023
Corrigendum: Compounds purified from edible fungi fight against chronic inflammation through oxidative stress regulation
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1081523
- 954 views
Review
Published on 04 Jan 2023
Research progress of nano selenium in the treatment of oxidative stress injury during hepatic ischemia-reperfusion injury
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1103483
- 2,266 views
- 7 citations
Editorial
Published on 04 Jan 2023
Editorial: Recent advances in novel therapeutic molecules and targets for inflammatory diseases
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1121821
- 1,557 views
- 2 citations
Editorial
Published on 04 Jan 2023
Editorial: Inflammation and aging in chronic and degenerative diseases: Current and future therapeutic strategies
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1122786
- 1,396 views
- 3 citations
Original Research
Published on 23 Dec 2022
Morroniside ameliorates inflammatory skeletal muscle atrophy via inhibiting canonical and non-canonical NF-ÎşB and regulating protein synthesis/degradation
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1056460
- 5,146 views
- 9 citations
Original Research
Published on 23 Dec 2022
Lonicerin attenuates house dust mite-induced eosinophilic asthma through targeting Src/EGFR signaling
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1051344
- 3,826 views
- 4 citations